Organ‐on‐a‐chip: Determine feasibility of a human liver microphysiological model to assess long‐term steroid metabolites in sports drug testing

A fundamental challenge in preventive doping research is the study of metabolic pathways of substances banned in sport. However, the pharmacological predictions obtained by conventional in vitro or in vivo animal studies are occasionally of limited transferability to humans according to an inability...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug testing and analysis 2021-11, Vol.13 (11-12), p.1921-1928
Hauptverfasser: Görgens, Christian, Ramme, Anja Patricia, Guddat, Sven, Schrader, Yvonne, Winter, Annika, Dehne, Eva‐Maria, Horland, Reyk, Thevis, Mario
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A fundamental challenge in preventive doping research is the study of metabolic pathways of substances banned in sport. However, the pharmacological predictions obtained by conventional in vitro or in vivo animal studies are occasionally of limited transferability to humans according to an inability of in vitro models to mimic higher order system physiology or due to various species‐specific differences using animal models. A more recently established technology for simulating human physiology is the “organ‐on‐a‐chip” principle. In a multichannel microfluidic cell culture chip, 3‐dimensional tissue spheroids, which can constitute artificial and interconnected microscale organs, imitate principles of the human physiology. The objective of this study was to determine if the technology is suitable to adequately predict metabolic profiles of prohibited substances in sport. As model compounds, the frequently misused anabolic steroids, stanozolol and dehydrochloromethyltestosterone (DHCMT) were subjected to human liver spheroids in microfluidic cell culture chips. The metabolite patterns produced and circulating in the chip media were then assessed by LC‐HRMS/(MS) at different time points of up to 14 days of incubation at 37°C. The overall profile of observed glucurono‐conjugated stanozolol metabolites excellently matched the commonly found urinary pattern of metabolites, including 3′OH‐stanozolol‐glucuronide and stanozolol‐N‐glucuronides. Similarly, but to a lower extent, the DHCMT metabolic profile was in agreement with phase‐I and phase‐II biotransformation products regularly seen in postadministration urine specimens. In conclusion, this pilot study indicates that the “organ‐on‐a‐chip” technology provides a high degree of conformity with traditional human oral administration studies, providing a promising approach for metabolic profiling in sports drug testing. With its basic idea to imitate principles of human physiology on a microchip, the recently established “organ‐on‐a‐chip” technology has been verified as a potential tool for metabolic profiling of substances banned in sport.
ISSN:1942-7603
1942-7611
DOI:10.1002/dta.3161